Surgical management of pancreatic neuroendocrine liver metastases

被引:30
作者
Cloyd, Jordan M. [1 ]
Wiseman, Jason T. [1 ]
Pawlik, Timothy M. [1 ]
机构
[1] Ohio State Univ Wexner, Dept Surg, Div Surg Oncol, 410 W 10th Ave,N907 Doan Hall, Columbus, OH 43210 USA
关键词
Carcinoid; liver resection; hepatectomy; pancreatic neuroendocrine tumor (PNET); transarterial chemoembolization (TACE); CONSENSUS-GUIDELINES; HEPATIC METASTASES; INTRAARTERIAL THERAPIES; REPEAT HEPATECTOMY; PROGNOSTIC-FACTORS; TUMORS; RESECTION; DISEASE; SURGERY; OUTCOMES;
D O I
10.21037/jgo.2019.11.02
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pancreatic neuroendocrine tumors (PNET) are a heterogeneous group of neoplasms that vary in their clinical presentation, behavior and prognosis. The most common site of metastasis is the liver. Surgical resection of neuroendocrine liver metastases (N ELM) is thought to afford the best long-term outcomes when feasible. Initial preoperative workup should include surveillance for carcinoid syndrome, screening for evidence of liver insufficiency, and performance of imaging specific to neuroendocrine tumors such as a somatostatin receptor positron emission tomography scan. Standard surgical principles apply to hepatic surgery for NELM, namely prioritizing low central venous pressure anesthesia, minimizing blood lass, knowledge of liver anatomy, generous use of intraoperative ultrasound, as well as safe parenchymal transaction techniques and practices to avoid bile leakage. Knowledge of established prognostic factors may assist with patient selection, which is important for optimizing short- and long-term outcomes of hepatic resection. Adjunct therapies such as concomitant liver ablation are used frequently and are generally safe when used appropriately. For patients with synchronous resectable NELM, resection of the primary either in a staged or combined fashion is recommended. Primary tumor resection in the setting of unresectable metastatic disease is more controversial, however generally recommended if morbidity is acceptable. For patients who arc not surgical candidates, due to either patient performance status or burden of liver disease, several liver-directed therapies such as transartcrial embolization, chemoembolization, and radioembolization are available to assist with locoregional control, extend progression-free survival (PH), and improve symptoms of carcinoid syndrome. Multiple systemic therapy options exist for patients with metastatic PNET which are often prioritized for those patients with advanced or progressive disease. A systematic approach in a multi-disciplinary setting is likely to result in the best long-term outcomes for patients with pancreatic NELM. Ongoing research is needed to determine the optimal patient selection for hepatic surgery as well as the ideal treatment sequencing for those patients with NELM.
引用
收藏
页码:590 / 600
页数:11
相关论文
共 75 条
[1]   Repeat hepatectomy for colorectal liver metastases [J].
Adam, R ;
Bismuth, H ;
Castaing, D ;
Waechter, F ;
Navarro, F ;
Abascal, A ;
Majno, P ;
Engerran, L .
ANNALS OF SURGERY, 1997, 225 (01) :51-60
[2]  
[Anonymous], 2009, COCHRANE DATABASE SY
[3]  
[Anonymous], 1997, ANN SURG
[4]  
[Anonymous], 2018, J CLIN ONCOL S
[5]   Neuroendocrine liver metastasis: The chance to be cured after liver surgery [J].
Bagante, Fabio ;
Spolverato, Gaya ;
Merath, Katiuscha ;
Postlewait, Lauren McLendon ;
Poultsides, George A. ;
Mullen, Matthew G. ;
Bauer, Todd W. ;
Fields, Ryan C. ;
Lamelas, Jorge ;
Marques, Hugo P. ;
Aldrighetti, Luca ;
Thuy Tran ;
Maithel, Shishir K. ;
Pawlik, Timothy M. .
JOURNAL OF SURGICAL ONCOLOGY, 2017, 115 (06) :687-695
[6]   Hepatic artery chemoembolization in 122 patients with metastatic carcinoid tumor: Lessons learned [J].
Bloomston, Mark ;
Al-Saif, Osama ;
Klemanski, Dori ;
Pinzone, Joseph J. ;
Martin, Edward W. ;
Palmer, Bryan ;
Guy, Gregory ;
Khabiri, Hooman ;
Ellison, E. Christopher ;
Shah, Manisha H. .
JOURNAL OF GASTROINTESTINAL SURGERY, 2007, 11 (03) :264-271
[7]  
Caplin ME, 2014, NEW ENGL J MED, V371, P224, DOI [10.1056/NEJMoa1316158, 10.1056/NEJMc1409757]
[8]   Hepatic cytoreduction followed by a novel long-acting somatostatin analog: A paradigm for intractable neuroendocrine tumors metastatic to the liver [J].
Chung, MH ;
Pisegna, J ;
Spirt, M ;
Giuliano, AE ;
Ye, W ;
Ramming, KP ;
Bilchik, AJ .
SURGERY, 2001, 130 (06) :954-962
[9]   Liver transplantation and multivisceral transplantation in the management of patients with advanced neuroendocrine tumours [J].
Clift, Ashley Kieran ;
Frilling, Andrea .
WORLD JOURNAL OF GASTROENTEROLOGY, 2018, 24 (20) :2152-2162
[10]   The emerging role of targeted therapies for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors [J].
Cloyd, Jordan M. ;
Konda, Bhavana ;
Shah, Manisha H. ;
Pawlik, Timothy M. .
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (02) :101-108